PREDICTIVE VALUE OF EASIX SCORES AT DIFFERENT TIME POINTS FOR PTLD AND SURVIVAL IN PATIENTS WITH EBV REACTIVATION AFTER ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION (EHA 2026) - May 12, 2026 - Abstract #EHA-5134; PF1153; Pres time: Jun 12, 2026; 06:45 PM - 07:45 PM; Location: Hall A; "Recent factors like the SARS-CoV-2 pandemic and letermovir prophylaxis may further increase EBV risks...Additionally, EASIX scores demonstrate a strong association with early mortality risk. Therefore, our findings support EASIX as a robust, universally accessible predictive marker for PTLD and a prognostic marker for outcome following EBV reactivation after allo-HSCT."
Clinical • Bone Marrow Transplantation • Hematological Malignancies • Infectious Disease • Lymphoma • Respiratory Diseases
|
|
Luxin Yang 1,2; Yi Luo 1,2
|